WASHINGTON — The Antiviral Drugs Advisory Committee of the Food and Drug Administration recommended the agency approve for preventative use Gilead’s AIDS treatment drug Truvada, according to MSNBC.
Testing has shown promise with high-risk patients in preventing HIV infection when taking the drug daily. Though concerns have been raised over the drug’s cost ($1,200 per month), the possibility for creating drug-resistant strains of the virus and side effects like nausea, HIV prevention specialists welcome the decision as part of a comprehensive toolkit to reducing new infections.
“Existing interventions have not reduced the number of new infections annually and new measures are needed,” Dr. John Mellors, chief of the infectious diseases division at the University of Pittsburgh, told MSNBC.
- State Department declines to comment on ‘lavender scare’ bill by Michael K. Lavers | posted on June 23, 2017
- Janet Mock says Caitlyn Jenner doesn’t represent transgender community by Mariah Cooper | posted on June 23, 2017
- ‘Pizzagate’ gunman sentenced to four years in jail by Lou Chibbaro Jr. | posted on June 23, 2017
- Shonda Rhimes to remake ‘Queer as Folk’ creator’s gay dramedies by Mariah Cooper | posted on June 23, 2017
- A fix for funding D.C.’s next-decade paid leave law by Mark Lee | posted on June 23, 2017